Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following with stage III/IV disease, and 50% with 4 previous treatment regimens. With a median follow-up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%-29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single-agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib.
| I N T R O D U C T I O N
Non-Hodgkin lymphoma (NHL) comprises a diverse group of hematologic malignancies, of which 85% to 90% have a B-cell origin. 1 Mantle cell lymphoma (MCL) accounted for fewer than 10% of all cases NHL and had an age-adjusted incidence of 0.55 per 100 000 person-years during the period 1992-2004. [2] [3] [4] The overall median survival in advanced non-blastoid MCL has improved, in large part through use of dose-intensified anthracycline-and cytarabine-based regimens, anti-CD20 monoclonal antibodies, novel targeted agents, and various doseintensive/high-dose strategies. 5, 6 Other considerations include the development of more effective salvage regimens, potentially as a bridge to allogeneic transplantation, the only potentially curative option, in eligible patients. 7 For all non-blastoid MCL patients, median overall survival (OS) continues to be 4 to 5 years with first-line therapy and 1 to 2 years for relapsed/refractory disease. 5, 8 Although most patients respond to first-line treatment, the duration of response (DOR) is relatively short, and successive relapses may be accompanied by chemoresistance. 8 As such, the goals of therapy are to enhance responses to treatment, extend DOR, and ultimately improve survival.
No standard of care or reliably curative treatment is currently available for patients with relapsed/refractory MCL. 9, 10 The mammalian target of rapamycin (mTOR) inhibitor temsirolimus was approved for relapsed/refractory MCL in the European Union (EU) in 2009 based on significant improvement in progression-free survival (PFS) compared to investigator's choice. 11 With approvals for MCL in both the US and EU, bortezomib, lenalidomide, and ibrutinib also have distinct mechanisms of action. [12] [13] [14] [15] [16] [17] The proteasome inhibitor bortezomib was approved for (10) 18 (13) 22 (14) 25 (12) MIPI score High ( 6.2) 32 (44) 39 (29) 54 (34) 71 (34) 15 (21) 41 (31) 46 (29) 56 (27) 10-<15 5 (7) 9 (7) 10 (6) 14 (7 prior treatment regimens (range, 1-13), with 56% receiving their last anti-lymphoma therapy less than 6 months prior.
In the MCL-001 study, eligible patients had received prior anthracycline (or mitoxantrone), cyclophosphamide, and rituximab and had relapsed or progressive disease within 12 months after bortezomib or were refractory to bortezomib. 28 The MCL-001 study cohort of 134 patients had a median age of 67 years, with predominantly advancedstage disease (93% stage III/IV, Table 1 ). Patients had received a median of 4 prior therapies (range, 2-10), with 78% who had received 3 prior treatment regimens.
Because of the similar study design and patient populations in each of these studies, the 3 MCL study populations from NHL-002, NHL-003, and MCL-001 trials have been combined for this analysis.
The combined patient populations from NHL-002/003 and the MCL-001 studies showed consistent baseline patient profiles, with or without prior bortezomib. Overall, 63% of MCL patients were 65 years of age or older, 71% had an intermediate to high MCL International Prognostic Index (MIPI) score; 52% showed high tumor burden); 30% presented with bulky disease; at study entry; and 33% had prior high-dose therapy (HDT) or dose-intensive therapy (DIT) including stem cell transplant, hyperCVAD, or R-hyperCVAD. None had received prior ibrutinib.
| Efficacy
In the combined group of all 206 MCL patients, lenalidomide produced CR/CRu in 11% of patients and PR in 22% of patients, resulting in an ORR of 33% (Table 2) . Stable disease was also reached in 32% of 
| Response rates across MCL subgroups
ORR with single-agent lenalidomide in the combined cohort was consistent across subgroups as defined by baseline demographics, clinical characteristics, or prior therapy (Table 3) . Patients with adverse prognostic factors, including high MIPI score, 35 high tumor burden, or bulky disease, and those who relapsed after or were refractory to bortezomib, or who received prior high-dose or high-intensity chemotherapy, had ORRs comparable to the ORR for the entire MCL cohort. One of the highest ORR was observed in patients who received lenalidomide starting 6 months after their last anti-lymphoma therapy (47%), and one of the lowest ORR included elevated lactate dehydrogenase (LDH, >250 U/L; 20%)
| Safety
Lenalidomide was initiated at a dose of 25 mg daily on days 1 to 21 of each 28-day cycle in these phases II trials, and at 10 mg for patients with moderate renal insufficiency characterized by creatinine clearance (21) 34 (22) 46 (22) SD, n (%) 27 (38) 38 (28) 48 (31) 65 (32) PD, n (%) 16 (22) 34 (25) 39 (25) 50 (24) Median TTR, months (range) 1. transitional cell carcinoma, breast cancer, esophageal carcinoma, metastatic colon cancer, metastatic lung adenocarcinoma, meningioma, metastatic squamous cell carcinoma, prostate cancer, and small cell lung 
| DISCUSSION
The availability of new treatments is changing the treatment approach for patients with MCL. Since these agents are now being moved upfront for the initial treatment of MCL, it is important to understand the longer-term outcomes and toxicities of these agents. These data will help design the optimal approach for the MCL patient. In this report, we provide long-term outcome data by combining the analysis of 3 phase II trials. We demonstrate that the ORR to lenalidomide across these studies was 33%, including 11% of patients with CR/CRu.
Responses appeared after a median of 2.2 months, lasting for a median of 16.6 months. The ORR is noteworthy, given that patients were heavily pretreated, having previously received a median of 4 treatment regimens, and 63% were 65 years of age. 
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